Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScience Group Regulatory News (SAG)

Share Price Information for Science Group (SAG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 427.00
Bid: 420.00
Ask: 434.00
Change: 3.00 (0.71%)
Spread: 14.00 (3.333%)
Open: 427.00
High: 427.00
Low: 427.00
Prev. Close: 424.00
SAG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Strategic Review

21 Sep 2018 07:00

RNS Number : 4764B
Science Group PLC
21 September 2018
 

 21 September 2018

 

 

Science Group plc

("Science Group" or "Group" or "Company")

 

Corporate Strategic Review

 

 

The Board of Science Group plc has decided to undertake a formal review of the Group's corporate strategy. The reasons for the review are set out below.

Background

Science Group comprises a cash generative consultancy business with two substantial freehold property (office/laboratory) assets which host the operating activities. In addition to providing dividends to shareholders and bonuses/profit share to employees, the Group's operational cash flow has been used to fund acquisitions and share buy-backs enabling the business to significantly increase in scale without shareholder dilution. The freehold property provides asset security to enable the Group to obtain low cost, long-term debt without onerous operating covenants (subject to debt level). The Board carefully considers the corporate allocation of cash resources and has provided analysis in year-end investor presentations for transparency. 

 

It is 8 years since the Chairman's investment which was the catalyst for a material change in the strategy of the Group. During this time the Board and the Management Team have been focused on the Group's organic and acquisitive strategies, resulting in substantial growth and consistently strong operating margins, underpinned by the Group's balance sheet. This foundation provides confidence to the Group's employees, customers and shareholders. But, in an ever changing world (eg Brexit), the Management and Board priorities continue to be to position the Group to address both challenges and opportunities as they arise. 

 

The Chairman remains the Group's largest shareholder at 33.5%. The top 3 shareholders (including the Chairman) hold around 60% and the top 10 shareholders control collectively around 80%. The Board recognises the limitations derived from the concentration of the Group's shareholder base including that the lack of share trading liquidity can be an inhibitor for some institutional investors and may correspondingly impact on valuation. Furthermore, due to the Group's strong operating cash flow and cash allocation model, the issued share capital of the Company today (excluding treasury shares) is less than it was in July 2010, despite the significant growth in operations.

 

Corporate Strategic Review Process

 

In the context of the above, and as the integration of TSG nears completion, the Board has determined that it is now appropriate to undertake a formal review of the Group corporate strategy. This review will cover a range of subjects including:

 

· The allocation of cash resources and asset utilisation;

· The shareholder structure and share liquidity;

· The potential diversification of the Group;

· The merits of the Group remaining as an independent organisation.

The Strategic Review is restricted to corporate aspects of the Group's strategy. The operations and organisational structure of the business are not part of the review. The operating model has progressively evolved to a structure providing a range of science-based services into key vertical market sectors and the Board and Management consider this to be the right model for the existing business. This operating strategy includes enhancing the organic development of the business through add-on acquisitions.

It must also be emphasised that Science Group has a very strong balance sheet and a track record of consistent financial performance. As such, the Board will undertake the review in a timely but structured manner, evaluating each of the above factors, and potentially others that may arise, in defining the future corporate strategy for the Group.

In order to avoid the Company being in a protracted period of uncertainty, the Board anticipates completing the Corporate Strategic Review by the time of the release of the Preliminary Results for 2018. The Board of Science Group plc reserves the right to alter or terminate the process at any time and will provide updates to shareholders as appropriate/required. 

 

Share Buy-Back Programme

 

In accordance with the terms of the Share Buy-Back Programme, Panmure Gordon have suspended this activity during the Strategic Review process.

 

 

For further information:

Science Group plc

Martyn Ratcliffe, Chairman

Tel: +44 (0) 1223 875 200

 

Panmure Gordon (UK) Limited

 

Dominic Morley

Tel: +44 (0) 20 7886 2500

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of the Market Abuse Regulation 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDLLFVDALIIFIT
Date   Source Headline
9th Jan 20237:00 amRNSRegulatory Clearance & Scheme Timetable Update
15th Dec 20227:00 amRNSPre-Close Trading and Business Update
14th Dec 20223:33 pmRNSResult of Court Meeting & General Meeting
30th Nov 20224:35 pmRNSTotal Voting Rights
30th Nov 20227:00 amRNSExercise of Share Options
24th Nov 20221:13 pmRNSHolding(s) in Company
21st Nov 20227:00 amRNSPublication of Scheme Document
10th Nov 20227:00 amRNSForm 8 (OPD) (TP Group plc)
7th Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
4th Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
3rd Nov 20224:35 pmRNSTreasury shares issued
3rd Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
2nd Nov 202210:44 amRNSForm 8 (DD) - TP Group plc
2nd Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
1st Nov 202210:33 amRNSRule 2.10 - M&G Letter of Intent
1st Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
31st Oct 20225:41 pmRNSTotal Voting Rights
31st Oct 20225:22 pmRNSForm 8 (OPD) - TP Group plc
31st Oct 20227:00 amRNSRecommended Cash Aquisition of TP Group plc
12th Oct 20224:55 pmRNSTreasury shares issued
30th Sep 20224:35 pmRNSTotal Voting Rights
28th Sep 20227:00 amRNSIssue of share options and PDMR dealing
21st Sep 20223:59 pmRNSTreasury shares issued
2nd Sep 20225:37 pmRNSTransaction in Own Shares
2nd Sep 20227:00 amRNSTransaction in Own Shares
1st Sep 20227:00 amRNSTotal Voting Rights
26th Aug 20225:47 pmRNSTransaction in Own Shares
10th Aug 20227:00 amRNSTransaction in Own Shares
9th Aug 20227:00 amRNSTransaction in Own Shares
2nd Aug 20225:18 pmRNSTransaction in Own Shares
29th Jul 20225:41 pmRNSTransaction in Own Shares
28th Jul 20225:53 pmRNSTransaction in Own Shares
27th Jul 20225:31 pmRNSTransaction in Own Shares
27th Jul 20223:24 pmRNSHolding(s) in Company
27th Jul 20227:00 amRNSTransaction in Own Shares
25th Jul 20227:00 amRNSInterim results for 6 months ended 30 June 2022
22nd Jul 20227:00 amRNSNotice of Interim Results
31st May 20224:40 pmRNSTotal Voting Rights
24th May 20225:31 pmRNSTransaction in Own Shares
23rd May 20225:15 pmRNSTransaction in Own Shares
19th May 20225:39 pmRNSHolding(s) in Company
19th May 20225:37 pmRNSHolding(s) in Company
18th May 20225:50 pmRNSTransaction in Own Shares
18th May 20221:17 pmRNSResult of AGM
18th May 20227:00 amRNSAGM Trading Update and NED Appointment
10th May 20224:45 pmRNSTreasury shares issued
29th Apr 20224:45 pmRNSTotal Voting Rights
12th Apr 20227:00 amRNSPosting of AGM documents & Notice of AGM
7th Apr 20227:23 amRNSTransaction in Own Shares
5th Apr 20225:30 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.